Galantamine may temporarily improve or stabilize memory and thinking in some people with mild-to-moderate Alzheimer's dementia, but it does not stop brain-cell damage. Its clearest candidates are people with that diagnosis and stage; risks include nausea, weight loss, slow heart rate, heart block, and fainting. Galantamine is a cholinesterase inhibitor, a medicine that supports signaling by the brain chemical acetylcholine. It treats symptoms rather than the underlying cause of Alzheimer's disease.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How much benefit can galantamine provide?
- Who fits the evidence—and who does not?
- The most common trade-off
- Heart risks and conditions requiring caution
- What to review with the prescriber
How much benefit can galantamine provide?
The Alzheimer's Association explains that galantamine may temporarily lessen or stabilize problems with memory and thinking by supporting acetylcholine signaling. It cannot stop Alzheimer's-related damage to brain cells in its overview of memory treatments. The average benefit in clinical trials was measurable but limited.
In a 21-week trial involving 978 people, daily doses of 16 and 24 mg improved ADAS-cog scores by 3.3 and 3.6 points versus placebo, respectively. This test measures cognitive performance. The higher dose was not significantly better than the 16-mg dose, according to the DailyMed/FDA drug label. That finding matters because more medication does not necessarily produce a more noticeable benefit.
Who fits the evidence—and who does not?
U.S. labeling indicates galantamine for mild-to-moderate dementia of the Alzheimer's type. It is not a general treatment for every illness that causes dementia. The supporting trials enrolled people with probable Alzheimer's disease and MMSE cognitive-test scores from 10 to 24.
The evidence therefore does not transfer directly to substantially milder impairment, severe dementia, or dementia caused by another condition. Galantamine is not FDA-indicated for mild cognitive impairment, or MCI. In two two-year MCI trials, 13 of 1,026 galantamine recipients died, compared with 1 of 1,022 placebo recipients. The FDA label notes that this difference conflicted with findings from other studies, but it remains an important reason not to treat MCI as equivalent to diagnosed Alzheimer's dementia.
The most common trade-off
Stomach and appetite problems are the most frequent practical drawback. Pooled trials reported nausea in 20.7% of galantamine recipients versus 5.5% with placebo.
Vomiting occurred in 10.5% versus 2.3%. Loss of appetite and weight loss also occurred, so clinicians should monitor weight. These effects can matter even when the medicine helps cognition, particularly if the person is already eating poorly or losing weight.
Heart risks and conditions requiring caution
Galantamine can slow the heart rate or cause heart block, even in someone without known electrical-conduction disease. Fainting increased with dose in trials, reaching 2.2% at 12 mg twice daily versus 0.7% with placebo. Prescribers should also use extra caution when a person has severe asthma or COPD, an ulcer or NSAID-related bleeding risk, or impaired kidney or liver function.
Dose adjustment or a different treatment may be necessary. Use is not recommended in severe hepatic impairment or when creatinine clearance—a measure used to assess kidney function—is below 9 mL/min. These gastrointestinal, cardiac, respiratory, bleeding, kidney, and liver precautions are detailed in the DailyMed/FDA prescribing information.
What to review with the prescriber
Before deciding on galantamine, the patient and care partner can help the prescriber assess whether its potential symptom benefit justifies its risks: During treatment, track nausea, vomiting, reduced appetite, weight loss, and fainting. Report concerning changes to the prescriber and reassess whether any cognitive stability or improvement outweighs the treatment burden.
- Confirm that the diagnosis is Alzheimer's dementia and that the current stage is mild to moderate.
- Mention fainting, a slow heart rate, breathing disease, ulcers, or regular NSAID use.
- Review known kidney or liver impairment.
- Record weight so later appetite or weight changes are easier to detect.
